The C677T and A1298C MTHFR polymorphisms did not differ in prevalence among individuals with CAD, DVT, or no vascular disease, though the 677TT genotype increased fasting tHcy (P<0.005).
Observational (n=1,238)
The A1298C MTHFR polymorphism, unlike the C677T polymorphism, is not associated with increased fasting homocysteine levels, and neither polymorphism's prevalence differs between patients with and without vascular disease.
p-value: p=<0.005
BACKGROUND: Moderately increased plasma concentrations of total homocysteine (tHcy) have been shown to be an important risk factor for vascular diseases. Two common polymorphisms of the methylenetetrahydrofolate reductase (MTHFR) gene, the thermolabile C677T and a more recently reported A1298C polymorphism, may contribute to hyperhomocysteinemia. METHODS: Using PCR and restriction fragment length polymorphism analysis, we studied the prevalence of the C677T and A1298C MTHFR genotypes and the combined effect of these polymorphisms on plasma tHcy concentrations, as measured by HPLC with fluorometric detection, both fasting and post-methionine load (PML), in 1238 individuals. RESULTS: The prevalences of the C677T and A1298C genotypes did not differ significantly in 772 individuals with documented coronary artery disease (CAD), 137 individuals with deep-vein thrombosis (DVT), and 329 individuals without documented vascular disease. Individuals homozygous for the 677T allele had significantly increased fasting tHcy, particularly in the presence of low folate, compared with individuals homozygous for the wild-type allele. Neither the 1298AC nor the 1298CC genotype was associated with significantly increased fasting or PML tHcy concentrations irrespective of serum folate. Of the nine combined MTHFR genotypes, six were present in >10% of the population. Of these, the difference in mean fasting tHcy reached statistical significance (P<0.005) only in individuals with the 677TT/1298AA genotype compared with individuals with the wild-type 677CC/1298AA genotype. Differences in mean fasting tHcy did not reach statistical significance in individuals heterozygous for both MTHFR variants. We detected two 677CT/1298CC and three 677TT/1298AC individuals; only one, an 677TT/1298AC individual, had increased tHcy (both fasting and PML). No individuals had the 677TT/1298CC genotype. CONCLUSIONS: The prevalences of the C677T and A1298C polymorphisms did not differ among individuals with CAD, DVT, or those without documented vascular disease. In contrast to the C677T polymorphism, the A1298C polymorphism is not associated with increased fasting tHcy. Although the two polymorphisms usually exist in trans configuration, crossover may occur rarely to form recombinant chromosomes.
Hanson et al. (2001) conducted an observational in Vascular disease (Coronary artery disease and Deep-vein thrombosis) (n=1,238). C677T and A1298C MTHFR polymorphisms vs. Wild-type MTHFR genotype was evaluated on Prevalence of genotypes and plasma tHcy concentrations (p=<0.005). The C677T and A1298C MTHFR polymorphisms did not differ in prevalence among individuals with CAD, DVT, or no vascular disease, though the 677TT genotype increased fasting tHcy (P<0.005).